A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
Purpose: To evaluate the treatment outcomes of aflibercept in patients with exudative age-related macular degeneration (AMD) resistant to other anti-vascular endothelial growth factor (VEGF) medications (bevacizumab, ranibizumab, and combination with or without dexamethasone and laser photocoagulati...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wolters Kluwer Medknow Publications
2014-04-01
|
| Rangatū: | Delhi Journal of Ophthalmology |
| Ngā marau: | |
| Urunga tuihono: | https://journals.lww.com/10.7869/djo.51 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|